Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ZENA
4701
ZenaTech Inc
ZENA
$118M
| $35.7K | ﹤0.01% |
11,163
+7,544
| +208% | +$31.4K |
2025 Q3
1 quarter
|
|
|
TVRD
4702
Tvardi Therapeutics
TVRD
$15.3M
| $35.7K | ﹤0.01% |
8,307
+1,638
| +25% | +$14.7K |
2025 Q2
2 quarters
|
|
|
APLS
4703
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $35.2K | ﹤0.01% |
+1,400
| New | +$32.8K |
2025 Q4
0 quarters
|
|
4704
Leslie's
LESL
$1.36M
| $35.2K | ﹤0.01% |
+21,306
| New | +$69.1K |
2025 Q4
0 quarters
|
|
|
JAJL
4705
Innovator Equity Defined Protection ETF - 6mo Jan/Jul
JAJL
$302M
| $35K | ﹤0.01% |
1,203
-3,672
| -75% | -$106K |
2025 Q2
2 quarters
|
|
4706
Palisade Bio
PALI
$251M
| $34.7K | ﹤0.01% |
+14,780
| New | +$28.4K |
2025 Q4
0 quarters
|
|
4707
flyExclusive
FLYX
$65.2M
| $34.7K | ﹤0.01% |
8,440
+983
| +13% | +$3.61K |
2025 Q3
1 quarter
|
|
4708
Caribou Biosciences
CRBU
$131M
| $34.5K | ﹤0.01% |
21,688
-84
| -0.4% | -$176 |
2022 Q1
15 quarters
|
|
4709
PMV Pharmaceuticals
PMVP
$95.7M
| $34.4K | ﹤0.01% |
27,536
| – | – |
2022 Q1
15 quarters
|
|
4710
Neonode
NEON
$15.5M
| $34.2K | ﹤0.01% |
19,680
+3,374
| +21% | +$8.93K |
2025 Q2
2 quarters
|
|
4711
Liberty Live Group Series A
LLYVA
$8.81B
| $33.8K | ﹤0.01% |
415
-983
| -70% | -$81.8K |
2023 Q4
8 quarters
|
|
4712
Kamada
KMDA
$480M
| $33.8K | ﹤0.01% |
4,788
+3,862
| +417% | +$26.7K |
2023 Q3
9 quarters
|
|
4713
Vroom Inc
VRM
$47.3M
| $33.6K | ﹤0.01% |
1,691
+175
| +12% | +$4.1K |
2025 Q2
2 quarters
|
|
4714
GeoPark
GPRK
$704M
| $33.5K | ﹤0.01% |
4,518
-1,131
| -20% | -$8.28K |
2025 Q1
3 quarters
|
|
4715
American Realty Investors
ARL
$259M
| $33.3K | ﹤0.01% |
2,072
+201
| +11% | +$3.17K |
2022 Q2
14 quarters
|
|
|
ORBS
4716
Eightco Holdings
ORBS
$499M
| $33.2K | ﹤0.01% |
+19,219
| New | +$90.2K |
2025 Q4
0 quarters
|
|
4717
Tilray
TLRY
$533M
| $33.1K | ﹤0.01% |
3,670
+860
| +31% | +$10.5K |
2021 Q1
19 quarters
|
|
4718
US GoldMining
USGO
$91.5M
| $32.9K | ﹤0.01% |
3,730
+1,358
| +57% | +$14.9K |
2025 Q2
2 quarters
|
|
4719
First Northwest Bancorp
FNWB
$94.6M
| $32.9K | ﹤0.01% |
3,503
-88
| -2% | -$800 |
2016 Q3
37 quarters
|
|
|
WW
4720
WW International
WW
$147M
| $32.8K | ﹤0.01% |
1,124
-445
| -28% | -$12.4K |
2025 Q3
1 quarter
|
|
|
VBNK
4721
VersaBank
VBNK
$726M
| $32.8K | ﹤0.01% |
2,190
| – | – |
2024 Q3
5 quarters
|
|
4722
Euroseas
ESEA
$511M
| $32.8K | ﹤0.01% |
600
| – | – |
2023 Q3
9 quarters
|
|
|
BNAI
4723
Brand Engagement Network
BNAI
$45.9M
| $32.6K | ﹤0.01% |
+14,041
| New | +$52.3K |
2025 Q4
0 quarters
|
|
4724
Direxion Daily CSI China Internet Index Bull 2X ETF
CWEB
$180M
| $32.1K | ﹤0.01% |
+800
| New | +$38.4K |
2025 Q4
0 quarters
|
|
4725
FT Vest US Equity Buffer ETF April
FAPR
$1.33B
| $31.7K | ﹤0.01% |
713
-3,892
| -85% | -$171K |
2024 Q3
5 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.